474 related articles for article (PubMed ID: 30536571)
1. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
3. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
4. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
5. New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.
Buľková V; Vargová J; Babinčák M; Jendželovský R; Zdráhal Z; Roudnický P; Košuth J; Fedoročko P
Biomed Pharmacother; 2023 Jul; 163():114829. PubMed ID: 37146419
[TBL] [Abstract][Full Text] [Related]
6. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
[TBL] [Abstract][Full Text] [Related]
8. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.
Vukovic M; Guitart AV; Sepulveda C; Villacreces A; O'Duibhir E; Panagopoulou TI; Ivens A; Menendez-Gonzalez J; Iglesias JM; Allen L; Glykofrydis F; Subramani C; Armesilla-Diaz A; Post AE; Schaak K; Gezer D; So CW; Holyoake TL; Wood A; O'Carroll D; Ratcliffe PJ; Kranc KR
J Exp Med; 2015 Dec; 212(13):2223-34. PubMed ID: 26642852
[TBL] [Abstract][Full Text] [Related]
9. Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition.
Hallis SP; Kim SK; Lee JH; Kwak MK
Redox Biol; 2023 Apr; 60():102632. PubMed ID: 36791645
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of hypoxia-inducible factors related to the invasiveness of epithelial ovarian cancer.
Shih HJ; Chang HF; Chen CL; Torng PL
Sci Rep; 2021 Nov; 11(1):22925. PubMed ID: 34824343
[TBL] [Abstract][Full Text] [Related]
11. HIF-1α forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells.
Zhu B; Pan S; Liu J; Wang S; Ni Y; Xiao L; Wei Q; Peng Y; Ding Z; Zhao W
Cell Biol Int; 2020 Feb; 44(2):456-466. PubMed ID: 31617641
[TBL] [Abstract][Full Text] [Related]
12. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer.
Zhang Q; Lou Y; Zhang J; Fu Q; Wei T; Sun X; Chen Q; Yang J; Bai X; Liang T
Mol Cancer; 2017 Jul; 16(1):119. PubMed ID: 28705232
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells.
Cui XY; Skretting G; Jing Y; Sun H; Sandset PM; Sun L
Blood Cells Mol Dis; 2013 Oct; 51(3):177-84. PubMed ID: 23725749
[TBL] [Abstract][Full Text] [Related]
15. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
Pastorek M; Simko V; Takacova M; Barathova M; Bartosova M; Hunakova L; Sedlakova O; Hudecova S; Krizanova O; Dequiedt F; Pastorekova S; Sedlak J
Int J Oncol; 2015 Jul; 47(1):51-60. PubMed ID: 25955133
[TBL] [Abstract][Full Text] [Related]
18. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
19. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
20. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.
Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH
Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
